Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Ripple Therapeutics

Request full access

Ripple Therapeutics : Highly Engineerable Drug Delivery Platform

Toronto, CanadaFounded 2019Biotech & Life Sciences

About Ripple Therapeutics

Ripple Therapeutics is a clinical-stage company specializing in the development of advanced drug delivery systems for ophthalmic therapeutics. Utilizing its proprietary Epidel technology, Ripple Therapeutics engineers drugs into controlled release pharmaceuticals and medical device coatings without the need for polymers or excipients. This technology allows for the creation of implantable forms such as cylinders and microspheres, which deliver drugs in a highly predictable manner based on surface erosion. The company operates in the pharmaceutical and medical device markets, focusing on clients in the ophthalmology sector. Ripple Therapeutics generates revenue through licensing deals, such as their agreement with Laboratoires for North America and Europe, and aims to achieve commercial success through innovative product development and strategic partnerships. The company is led by a seasoned leadership team experienced in managing both small and large public and private companies through various stages of growth and financing strategies, including venture capital, M&A transactions, IPOs, and PIPEs. Ripple Therapeutics also invests in the future by providing meaningful work experiences for university students through co-operative education programs.

Source: Dealroom company data

At a glance

Founded
2019
Headquarters
Toronto, Canada
Sector
Biotech & Life Sciences

Ripple Therapeutics in the Toronto ecosystem

Live from Dealroom

The Ripple Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed4 investors entered at this stage

  • Covington Funds
  • MaRS Investment Accelerator Fund
  • DSM Firmenich
  • National Research Council Canada

Series A1 investor entered at this stage

  • Théa Open Innovation
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇨🇦 Canada94.6%
🇺🇸 United States5.4%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Ripple Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Ripple Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.